Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 6/2015

Open Access 01-06-2015 | Research Article

μ-Opioid receptor gene (OPRM1) polymorphism in patients with breast cancer

Authors: Anna Cieślińska, Edyta Sienkiewicz-Szłapka, Elżbieta Kostyra, Ewa Fiedorowicz, Jadwiga Snarska, Konrad Wroński, Michał Tenderenda, Beata Jarmołowska, Michał Matysiewicz

Published in: Tumor Biology | Issue 6/2015

Login to get access

Abstract

Structure-dependent μ-opioid receptor (MOR) activity is an important element in cancer opioid analgesic effectiveness. It is widely accepted that guanine (G) substitution for adenine (A) at OPRM1 gene sequence position 118 changes receptor glycosylation pattern. This is associated with decreased binding ability in both exogenous and endogenous opioids, resulting in increased human pain resistance. The endogenous opioid system’s function in body homeostasis maintenance is considered mainly regulatory, so its participation in breast tumor formation and progression is identified herein. We examine the association of the most frequent MOR (A118G) gene polymorphism on breast cancer risk in a Northeastern Polish population by PCR-RFLP comparison of A and G allele frequency at OPRM1 gene A118G polymorphic site in breast cancer-diagnosed patients with healthy control group frequencies. Our results highlight a strong association between G allele presence at μ-opioid receptor A118G and increased breast cancer incidence (OR = 3.3, 95 % CI 2.2–5.0, p < 0.0001) and female gender (OR = 2.0, 95 % CI 1.4–2.9, p = 0.0004). Consequently, OPRM1 G allele presence at that site is a highly significant risk factor in breast cancer development.
Literature
1.
GLOBOCAN 2012 (IARC). Breast cancer: estimated incidence, mortality and prevalence worldwide in 2012. Lyon, France. International Agency for Research on Cancer. 2013. http://​globocan.​iarc.​fr. Accessed 28 Jul 2014.
2.
Gronwald J, Byrski T, Huzarski T, Oszurek O, Janicka A, Szymańska-Pasternak J, et al. Hereditary breast and ovarian cancer. Postępy Nauk Med. 2008;7:446–55.
3.
Peng S, Lu B, Ruan W, Yimin Zhu Y, Sheng H, Lai M. Genetic polymorphisms and breast cancer risk: evidence from meta-analyses, pooled analyses, and genome-wide association studies. Breast Cancer Res Treat. 2011;127:309–24.CrossRefPubMed
4.
Goody RJ, Kitchen I. Influence of maternal milk on functional activation of δ-opioid receptors in postnatal rats. J Pharmacol Exp Ther. 2001;296(3):744–8.PubMed
5.
Kieffer BL, Gavériaux-Ruff C. Exploring the opioid system by gene knockout. Prog Neurobiol. 2002;66(5):285–306.CrossRefPubMed
6.
Campana G, Sarti D, Spampinato S, Raffaeli W. Long-term intrathecal morphine and bupivacaine upregulate MOR gene expression in lymphocytes. Int Immunopharmacol. 2010;10:1149–52.CrossRefPubMed
7.
Cadet P, Mantione K, Bilfinger TV, Stefano GB. Morphine down regulates human vascular tissue estrogen receptor expression determined by real time PCR. Neuroendocrinol Lett. 2002;23:95–100.PubMed
8.
Hatzoglou A, Ouafik L, Bakogeorgou E, Thermos K, Castanas E. Morphine cross-reacts with somatostatin receptor SSTR2 in the T47D human breast cancer cell line and decreases cell growth. Cancer Res. 1995;55(23):5632–6.PubMed
9.
Gupta K, Kshirsagar S, Chang L, Schwartz R, Law PY, Yee D, et al. Morphine stimulates angiogenesis by activating proangiogenic and survival-promoting signaling and promotes breast tumor growth. Cancer Res. 2002;62:4491–8.PubMed
10.
Lazarczyk M, Matyja E, Lipkowski AW. A comparative study of morphine stimulation and biphalin inhibition of human glioblastoma T98G cell proliferation in vitro. Peptides. 2010;31:1606–12.CrossRefPubMed
11.
Afsharimani B, Cabot P, Parat MO. Morphine and tumor growth and metastasis. Cancer Metastasis Rev. 2011;30:225–38.CrossRefPubMed
12.
Mathew B, Lennon FE, Siegler J, Mirzapoiazova T, Mambetsariev N, Sammani S, et al. The novel role of the mu opioid receptor in lung cancer progression: a laboratory investigation. Anesth Analg. 2011;112(3):558–67.CrossRefPubMed
13.
Gach K, Wyrębska A, Fichna J, Janecka A. The role of morphine in regulation of cancer cell growth. Naunyn Schmiedebergs’ Arch Pharmacol. 2011;384(3):221–30.CrossRef
14.
Gach K, Piestrzeniewicz M, Fichna J, Stefanska B, Szemraj J, Janecka A. Opioid-induced regulation of μ-opioid receptor gene expression in the MCF-7 breast cancer cell line. Biochem Cell Biol. 2008;86(3):217–26.CrossRefPubMed
15.
Hatzoglou A, Bakogeorgou E, Castanas E. The antiproliferative effect of opioid receptor agonists on the T47D human breast cancer cell line is partially mediated through opioid receptors. Eur J Pharmacol. 1996;296:199–207.CrossRefPubMed
16.
Maneckjee R, Biswas R, Vonderhaar BK. Binding of opioids to human MCF-7 breast cancer cells and their effects on growth. Cancer Res. 1990;50:2234–8.PubMed
17.
Zagon IS, McLaughlin PJ, Goodman SR, Rhodes RE. Opioid receptors and endogenous opioids in diverse human and animal cancers. J Natl Cancer Inst. 1987;79:1059–65.PubMed
18.
Chatikhine VA, Chevrier A, Chauzy C, Duval C, d’Anjou J. Expression of opioid peptides in cells and stroma of human breast cancer and adenofibromas. Cancer Lett. 1994;7:51–6.CrossRef
19.
Gach K, Szemraj J, Fichna J, Piestrzeniewicz M, Delbro DS, Janecka A. The influence of opioids on urokinase plasminogen activator on protein and mRNA level in MCF-7 breast cancer cell line. Chem Biol Drug Des. 2009;74:390–6.CrossRefPubMed
20.
Gach K, Szemraj J, Wyrebska A, Janecka A. The influence of opioids on matrix metalloproteinase-2 and -9 secretion and mRNA levels in MCF-7 breast cancer cell line. Mol Biol Rep. 2011;38:1231–6.CrossRefPubMed
21.
Sueoka E, Sueoka N, Kai Y, Okabe S, Suganuma M, Kanematsu K, et al. Anticancer activity of morphine and its synthetic derivative, KT-90, mediated through apoptosis and inhibition of NF-kappaB activation. Biochem Biophys Res Commun. 1998;252:566–70.CrossRefPubMed
22.
Kasai S, Ikeda K. Pharmacogenomics of the human μ-opioid receptor. Pharmacogenomics. 2011;12:1305–20.CrossRefPubMed
23.
Mura E, Govoni S, Racchi M, Carossa V, Ranzani GN, Allegri M, et al. Consequences of the 118A>G polymorphism in the OPRM1 gene: translation from bench to bedside? J Pain Res. 2013;6:331–53.CrossRefPubMedPubMedCentral
24.
Klepstad P, Rakvag TT, Kaasa S, Holthe M, Dale O, Borchgrevink PC, et al. The 118A/G polymorphism in the human micro-opioid receptor gene may increase morphine requirements in patients with pain caused by malignant disease. Acta Anaesthesiol Scand. 2004;48:1232–9.CrossRefPubMed
25.
Chou WY, Yang LC, Lu HF, Ko JY, Wang CH, Lin SH, et al. Association of mu-opioid receptor gene polymorphism (A118G) with variations in morphine consumption for analgesia after total knee arthroplasty. Acta Anaesthesiol Scand. 2006;50:787–92.CrossRefPubMed
26.
Skarke C, Darimont J, Schmidt H, Geisslinger G, Lotsch J. Analgesic effects of morphine and morphine-6-glucuronide in a transcutaneous electrical pain model in healthy volunteers. Clin Pharmacol Ther. 2003;73:107–21.CrossRefPubMed
27.
Ikeda K, Ide S, Han W, Hayashida M, Uhl GR, Sora I. How individual sensitivity to opiates can be predicted by gene analyses. Trends Pharmacol Sci. 2005;26:311–7.CrossRefPubMed
28.
Fillingim RB, Kaplan L, Staud R, Ness TJ, Glover TL, Campbell CM, et al. The A118G single nucleotide polymorphism of the mu-opioid receptor gene (OPRM1) is associated with pressure pain sensitivity in humans. J Pain. 2005;6:159–67.CrossRefPubMed
29.
Bortsov AV, Millikan RC, Belfer I, Boortz-Marx RL, Arora H, McLean SA. μ-Opioid receptor gene A118G polymorphism predicts survival in patients with breast cancer. Anesthesiology. 2012;116(4):896–902.CrossRefPubMedPubMedCentral
30.
Wang S, Li Y, Liu X-D, Zhao C-Z, Yang K-Q. Polymorphism of A118G in u-opioid receptor gene is associated with risk of esophageal squamous cell carcinoma in a Chinese population. Int J Clin Oncol. 2013;18(4):666–9.CrossRefPubMed
31.
Jarmołowska B, Sidor K, Iwan M, Bielikowicz K, Kaczmarski M, Kostyra E, et al. Changes of β-casomorphin content in human milk during lactation. Peptides. 2007;28:1982–6.CrossRefPubMed
32.
Romberg RR, Olofsen E, Bijl H, Taschner PE, Teppema LJ, Sarton EY, et al. Polymorphism of mu-opioid receptor gene (OPRM1:c.118A>G) does not protect against opioid-induced respiratory depression despite reduced analgesic response. Anesthesiology. 2005;102(3):522–30.CrossRefPubMed
33.
Sidor K, Jarmołowska B, Kaczmarski M, Kostyra E, Iwan M, Kostyra H. Content of β-casomorphins in milk of women with a history of allergy. Pediatr Allergy Immunol. 2008;9(7):587–91.CrossRef
34.
Ray R, Jepson C, Patterson F, Strasser A, Rukstalis M, Perkins K, et al. Association of OPRM1 A118G variant with the relative reinforcing value of nicotine. Psychopharmacology. 2006;188:355–63.CrossRefPubMed
35.
Munafo MR, Elliot KM, Murphy MF, Walton RT, Johnstone EC. Association of the mu-opioid receptor gene with smoking cessation. Pharmacogenomics J. 2007;7:353–61.CrossRefPubMed
36.
Kim SG. Gender differences in the genetic risk for alcohol dependence—the results of a pharmacogenetic study in Korean alcoholics. Nihon Arukoru Yakubutsu Igakkai Zasshi. 2009;44:680–5.PubMed
37.
Miao H, Verkooijen HM, Chia KS, Bouchardy C, Pukkala E, Laronningen S, et al. Incidence and outcome of male breast cancer: an international population-based study. J Clin Oncol. 2011;29:4381–6.CrossRefPubMed
38.
Greif JM, Pezzi CM, Klimberg VS, Bailey L, Zuraek M. Gender differences in breast cancer: analysis of 13,000 breast cancers in men from the National Cancer Data Base. Ann Surg Oncol. 2012;19(10):3199–04.CrossRefPubMed
39.
Farooqui M, Geng ZH, Stephenson EJ, Zaveri N, Yee D, Gupta K. Naloxone acts as an antagonist of estrogen receptor activity in MCF-7 cells. Mol Cancer Ther. 2006;5(3):611–20.CrossRefPubMed
40.
Cadet P, Bilfinger TV, Fimiani C, Peter D, Stefano GB. Human vascular and cardiac endothelia express mu opiate receptor transcripts. Endothelium. 2000;7(3):185–91.CrossRefPubMed
Metadata
Title
μ-Opioid receptor gene (OPRM1) polymorphism in patients with breast cancer
Authors
Anna Cieślińska
Edyta Sienkiewicz-Szłapka
Elżbieta Kostyra
Ewa Fiedorowicz
Jadwiga Snarska
Konrad Wroński
Michał Tenderenda
Beata Jarmołowska
Michał Matysiewicz
Publication date
01-06-2015
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 6/2015
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-3113-z

Other articles of this Issue 6/2015

Tumor Biology 6/2015 Go to the issue

Research Article

Protein kinase D2 silencing reduced motility of doxorubicin-resistant MCF7 cells

Research Article

Combined therapy with CTL cells and oncolytic adenovirus expressing IL-15-induced enhanced antitumor activity

Research Article

Exosomal onco-miRs from serum of patients with adenocarcinoma of the esophagus: comparison of miRNA profiles of exosomes and matching tumor

Research Article

Defective Beclin-1 and elevated hypoxia-inducible factor (HIF)-1α expression are closely linked to tumorigenesis, differentiation, and progression of hepatocellular carcinoma

Research Article

Utility of tumor marker HE4 as prognostic factor in endometrial cancer: a single-center controlled study

Research Article

Acquisition of docetaxel resistance in breast cancer cells reveals upregulation of ABCB1 expression as a key mediator of resistance accompanied by discrete upregulation of other specific genes and pathways
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits